• 제목/요약/키워드: cell therapy%2C

검색결과 337건 처리시간 0.03초

Ex vivo Boosted Immune Cell Therapy for Canine Hepatic Disease

  • Bae, Seulgi;Oh, Taeho
    • 한국임상수의학회지
    • /
    • 제38권4호
    • /
    • pp.179-183
    • /
    • 2021
  • A 12-year-old male American Cocker Spaniel was diagnosed with a type of chronic hepatits (CH) called cholangioheaptits. Routine supportive medication was administered to the patient, and ex vivo boosted immune cell (EBI-C) therapy was used for the treatment. A histopathologic examination of the liver 19 months later revealed that the cholangiohepatitis had progressed to cholangiocarcinoma. The medication and immune cell therapy was maintained. Two months after the new diagnosis, the patient's state worsened, and the dog died 635 days after the first visit. EBI-C therapy is a type of immunotherapy, where immune cells are isolated from the patient's peripheral blood mononuclear cells, expanded ex vivo, and then infused into the patient intravenously every two weeks. EBI-Cs (mean: 2.78 × 108 cells) were obtained 38 times and infused every two weeks. Most EBI-C were T-lymphocytes (99.24% of total EBI cells). T-lymphocytes produce large interferon (IFN)-γ, and IFN-γ inhibits liver fibrosis in dogs with CH. Moreover, in bile duct cancer, an increase in T-lymphocytes correlates with decreasing tumor invasion and metastasis. Thus, we propose that EBI-C therapy is applicable as a new supportive therapy for canine liver disease if other treatments like drug medication, surgery, or radiation are unavailable.

Expression and Characterization of Purinergic Receptor, $P2Y_{10}$ in Hematopoietic Stem Cells

  • Lee Eun-Jong;Kim Dong-Ku
    • Reproductive and Developmental Biology
    • /
    • 제29권2호
    • /
    • pp.109-115
    • /
    • 2005
  • Hematopoietic stem cells (HSC) are multipotent cells that reside in the bone marrow and replenish all adult hematopoietic lineages throughoutthe lifetime. In this study, we analyzed the expression of receptors of $P2Y_{10}$, purinergic receptor families in murine hematopoietic stem cells, hematopoietic progenitor cells. In addition, the biological activity of $P2Y_{10}$ was investigated with B lymphocyte cell line, Ba/F3 in effect to cell growth and cell cycle. From the analysis of expression in hematopoieticstem cell. and progenitor with RT-PCR, $P2Y_{10}$ was strongly expressed in murine hematopoieticstem cells (c-kit+ Sca-l+ Lin-) and progenitor cell population, such as c-kit- Sca-l+ Lin-, c-kit+ Sca-l- Lin- and c-kit- Sca-l- Lin-. To investigate the biological effects by $P2Y_{10}$, retroviral vector from subcloned murine $P2Y_{10}$ cDNA was used fur gene introduction into Ba/F3 cells, and stable transfectant cells were obtained by flow cytometry sorting. In cell proliferation assay, the proliferation ability of $P2Y_{10}$ receptor gene­transfected cells was strongly inhibited, and the cell cycle was arrested at G1 phase. These result suggest that the $P2Y_{10}$ may be involved the biological activity in hematopoietic stem cells and immature B lymphocytes.

외과적 치료 없이 관해된 피부 역형성 대세포 림프종 1예 (A Case of Multifocal Primary Cutaneous Anaplastic Large Cell Lymphoma Managed without Surgical Treatment)

  • 임준호;박언주;은석찬
    • 대한두경부종양학회지
    • /
    • 제35권2호
    • /
    • pp.77-80
    • /
    • 2019
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is rare among skin malignancies. C-ALCL usually manifests as reddish or violet nodules. Surgical excision or radiation therapy is generally considered as first-line therapy, but a clinically aggressive disease may require multiagent chemotherapy. Establishing a proper diagnosis of C-ALCL is challenging but should be made to avoid inappropriate treatment and its consequences. The authors report a case of medically resolved C-ALCL in an 81-year-old man presented with well-defined nodular lesions on the forehead.

T2N0M0 비소세포성 폐암의 근치적 방사선치료 (Curative Radiation Therapy for T2N0M0 Non-small Cell Lung Cancer)

  • 박인규;김재철
    • Radiation Oncology Journal
    • /
    • 제13권1호
    • /
    • pp.19-26
    • /
    • 1995
  • Purpose : Surgery is the treatment of choice for resectable non-small cell lung cancer. For patients who are medically unable to tolerate a surgical resection or who refuse surgery, radiation therapy is an acceptable alternative. A retrospective analysis of Patients with stage I non-samll cell lung cancer treated with curative radiation therapy was performed to determine the results of curative radiation therapy and patterns of failure, and to identify factors that may influence survival. Materials and Methods : From 1986 through 1993, 39 Patients with T2N0M0 non-small cell lung cancer were treated with curative radiation therapy at department of radiation oncology, Kyungpook national university hospital. All Patients were not candidates for surgical resection because of either Patient refusal (16 patients), poor pulmonary function (12 patients), old age (7 patients), Poor Performance (2 patients) or coexisting medical disease (2 patients). Median age of patients was 67 years. Histologic cell type was squamous cell carcinoma in 36, adenocarcinoma in 1, large cell carcinoma in 1 and mucoepidermoid carcinoma in 1. All patients were treated with megavoltage irradiation and radiation dose ranged from 5000cgy to 6150cGy with a median dose of 6000cGy. The median follow-up was 17 months with a range of 4 to 82 months, Survival was measured from the date therapy initiated. Results : The overall survival rate for entire Patients was $40.6\%$ at 2 years and $27.7\%$ at 3 years, with a median survival time of 21 months. The disease-free survival at 2 and 3 years was $51.7\%$ and $25.8\%$, respectively. Of evaluable 20 patients with complete response, 15 patients were considered to have failed. Of these, 13 patients showed local failure and 2 patients failed distantly. Response to treatment (p=0.0001), tumor size (p=0.0019) and age (p=0.0247) were favorably associated with overall survival. Only age was predictive for disease-free survival (p = 0.0452). Conclusion : Radiation therapy is an effective treatment for small (less than 3cm) tumors, and should be offered as an alternative to surgery in elderly or infirm patients. Since local failure is the prominent Patterns of relapse, potential methods to improve local control with radiation therapy are discussed.

  • PDF

Reduction of Proliferation and Induction of Apoptosis are Associated with Shrinkage of Head and Neck Squamous Cell Carcinoma due to Neoadjuvant Chemotherapy

  • Sarkar, Shreya;Maiti, Guru Prasad;Jha, Jayesh;Biswas, Jaydip;Roy, Anup;Roychoudhury, Susanta;Sharp, Tyson;Panda, Chinmay Kumar
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권11호
    • /
    • pp.6419-6425
    • /
    • 2013
  • Background: Neoadjuvant chemotherapy (NACT) is a treatment modality whereby chemotherapy is used as the initial treatment of HNSCC in patients presenting with advanced cancer that cannot be treated by other means. It leads to shrinkage of tumours to an operable size without significant compromise to essential oro-facial organs of the patients. The molecular mechanisms behind shrinkage due to NACT is not well elucidated. Materials and Methods: Eleven pairs of primary HNSCCs and adjacent normal epithelium, before and after chemotherapy were screened for cell proliferation and apoptosis. This was followed by immunohistochemical analysis of some cell cycle (LIMD1, RBSP3, CDC25A, CCND1, cMYC, RB, pRB), DNA repair (MLH1, p53) and apoptosis (BAX, BCL2) associated proteins in the same set of samples. Results: Significant decrease in proliferation index and increase in apoptotic index was observed in post-therapy tumors compared to pre-therapy. Increase in the RB/pRB ratio, along with higher expression of RBSP3 and LIMD1 and lower expression of cMYC were observed in post-therapy tumours, while CCND1 and CDC25A remained unchanged. While MLH1 remained unchanged, p53 showed higher expression in post-therapy tumors, indicating inhibition of cell proliferation and induction of apoptosis. Increase in the BAX/BCL2 ratio was observed in post-therapy tumours, indicating up-regulation of apoptosis in response to therapy. Conclusions: Thus, modulation of the G1/S cell cycle regulatory proteins and apoptosis associated proteins might play an important role in tumour shrinkage due to NACT.

뇌하수체상부 배아세포종의 방사선치료 성적 (Radiation Therapy of Suprasellar Germ Cell Tumors)

  • 박우윤;최두호;최은경;김일한;하성환;박찬일
    • Radiation Oncology Journal
    • /
    • 제6권2호
    • /
    • pp.169-176
    • /
    • 1988
  • 1979년부터 1985년까지 서울대학교병원 치료방사선과에서 외부 방사선조사를 시행한 15명의 뇌하수체상부 배아세포종(전이송과선종) 환자에 대한 후향적 분석을 시행하였다. 생존자의 추적기간은 $30\~91$개월이었다. 10명의 환자는 방사선치료 전 조직학적으로 진단되었으며 나머지 5명은 조직학적 진단이 없이 방사선치료를 시행하였단 조직학적으로 진단된 9명중 배아세포종 환자 6명은 전뇌와 척추에 3명은 전뇌 조사를 시행하였다. 혼합 배아세포종 및 종양 marker양성인 5명의 환자 중 2명은 전뇌, 그리고 1명은 원발병소 부위에만 방사선치료를 시행하였다. 총 방사선량은 원발병소에 $5,000\~5,500 cGy$, 전뇌에 $3,000\~4,400 cGy$ 그리고 척추에 >$1,300\~3,000 cGy$였다. 상기 그룹 14명의 환자에서 원발병소는 완전 관해 되었으며 척추실패는 관찰되지 많았다. 조직학적 진만이 없고 marker의 상승이 없었던 한 환자에서 전뇌 방사선조사를 시행하였으나 원발병소의 완전관해 없이 척추 재발이 발생하였다. 방사선치료는 뇌하수체상부 배아세포종에 유효한 치료방법이며 신경 내분비학적 양상과 함께 조직학적 진단이 불가능한 경우에 있어서 소량의 방사선치료 후 관해정도 관찰은 이후의 치료방향설정에 유용한 수단으로 이용될 수 있다.

  • PDF

비소세포성 폐암의 방사선 치료 (Radiation Therapy in Non-Small Cell LUNG Cancer)

  • 한혜경;이명자
    • Radiation Oncology Journal
    • /
    • 제6권1호
    • /
    • pp.35-39
    • /
    • 1988
  • From Jan.1984 to Dec. 1986, 90 patients with lung cancer were treated at the Department of Radiation Therapy in Hanyang University Hospital. Histopathologically, 67 cases of them were the squamous cell carcinoma,7 cases were the adenocarcinoma, 4 cases were the large cell undiffe rentiated carcinoma and 12 cases were the small cell carcinoma. Among the 78 patients with non small cell carcinoma, 50 patients had received radiation dosage above 4000 cGy.40 patient had follow up from 17 months to 53 months. The complete response rate was $7.3\%$ and partial response rate was $68.3\%$. Overall survival at 1, 2 and 3 years were $47.5\%,\;23.5\%\;and\;6.3\%$ respectively. None was survived longer than 38 months. Median survival was 12.2 month for 40 patient and 9 month for stage III, M1 group and 9.5 month for stage III, MO group. In M1 patient no survival was seen after 2 years while in M0 patient $23.3\%$ survival was seen.

  • PDF